J
James A. Bonner
Researcher at University of Alabama at Birmingham
Publications - 252
Citations - 17463
James A. Bonner is an academic researcher from University of Alabama at Birmingham. The author has contributed to research in topics: Radiation therapy & Cetuximab. The author has an hindex of 56, co-authored 237 publications receiving 16175 citations. Previous affiliations of James A. Bonner include University of Alabama & University of Michigan.
Papers
More filters
Journal ArticleDOI
1546P Impact of stratification factors on outcomes in limited-stage small cell lung cancer: Analysis of CALGB 30610 (Alliance)/RTOG 0538
Jeffrey A. Bogart,X. S. Wang,Gregory A. Masters,J. Gao,Ritsuko Komaki,Laurie E. Gaspar,John V. Heymach,James A. Bonner,Charles S. Kuzma,Saiama N. Waqar,W. Jeffrey Petty,Thomas E. Stinchcombe,Jeffrey D. Bradley,EE Vokes +13 more
TL;DR: For example, this article found that gender, ECOG performance status (PS), weight loss > 5% prior to study entry, timing of initiating radiotherapy (chemotherapy cycle 1 vs cycle 2), radiotherapy planning technique (3D conformal vs intensity modulated), and carboplatin or cisplatin-based chemotherapy.
Journal ArticleDOI
Commentary on “Small-Cell Lung Cancer at the Millennium: Radiotherapy Innovations”
TL;DR: It is suggested that early TRT (compared to late TRT) may only show a detectable advantage for patients with favorable LSCLC and a low likelihood of gross metastatic disease, and caution should be exercised when comparing subpopulations.
Phase I II C omparison o f T wice-Daily S plit-Course Irradiation V ersus O nce-Daily I rradiation f or P atients With L imited S tage S mall-Cell L ung C arcinoma
James A. Bonner,Jeff A. Sloan,Thomas G. Shanahan,Burke J. Brooks,Randolph S. Marks,James E. Krook,James B. Gerstner,Andrew W. Maksymiuk,Ralph Levitt,James A. Mailliard,Henry D. Tazelaar,Shauna Hillman,James R. Jett +12 more
TL;DR: When TI is delayed until the fourth cycle of chemotherapy, TDTI does not result in improvement in local control or survival compared with ODTI.
Journal ArticleDOI
Lipid microsphere bound oxycodone for pain management in patients receiving radiotherapy for head and neck cancer.
Andrew M. McDonald,Sharon A. Spencer,Christopher D. Willey,James A. Bonner,Michael C. Dobelbower,Thomas A. Swain,Lisle Nabell,Susan McCammon,William R. Carroll,Gerald McGwin,Smita Bhatia,Eddy S. Yang +11 more
TL;DR: These results support the feasibility and safety of microsphere oxycodone for extended release analgesia among patients with HNC undergoing RT and would not need to be discontinued due to dysphagia or gastrostomy tube dependence.
The O utcome o f C ombined-Modalit y T herapy f or S tage I II Non-Small-Cell L ung C ancer i n t he E lderly
Steven E. Schild,Philip J. Stella,Susan Geyer,James A. Bonner,William L. McGinnis,James A. Mailliard,Jeffery Brindle,Aminah Jatoi,James R. Jett +8 more
TL;DR: Toxicity, especially myelosuppression and pneumonitis, was more pronounced in the elderly patients receiving combined-modality therapy for locally advanced NSCLC, and fit, elderly patients with locally advancedNSCLC should be encouraged to receive combined- modality therapy, preferably on clinical trials with cautious, judicious monitoring.